Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 5/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.61 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.57 |
| ▸ | THRA | P10827 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11301144 | 0.89 | PTGER1 (0.52) | PTGER1PTGER4PTGER3PTGER2PTGDR2 | |
| SCHEMBL3997102 | 0.86 | FFAR4 (0.64) | PTGER1PTGER4PTGER3PTGER2PTGDR2 | |
| SCHEMBL1355002 | 0.84 | PTGDR2 (0.52) | PTGER1PTGER4PTGER3PTGER2PTGDR2 | |
| SCHEMBL11297633 | 0.82 | PTGDR2 (0.63) | PTGER1PTGDR2 | |
| SCHEMBL3961129 | 0.82 | ALDH1A1 (0.49) | PTGER1PTGER4PTGER3PTGER2PTGDR2 | |
| SCHEMBL27506402 | 0.81 | PTGER1 (0.47) | PTGER1PTGER4PTGER3PTGER2PTGDR2 | |
| SCHEMBL16294058 | 0.80 | PTGER1 (0.64) | PTGER1PTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL3020588 | 0.80 | PTGER1 (0.59) | PTGER1PTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL1747327 | 0.80 | FFAR1 (0.67) | FFAR1FFAR4THRATHRBAKR1B1 | |
| SCHEMBL3884456 | 0.79 | FFAR1 (0.60) | PTGER1PTGER4PTGER3PTGER2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-05-26 | — | — | US | disclosed |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG | 2004-09-23 | — | — | US | disclosed |
| EP-1077912-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | PTGER1 361/4885PTGER4 468/4885PTGER3 108/4885 |
| US-20110124903-A1 | SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES | FES, NISCH, RPS27A | PTGER1 2625/4885PTGER4 2510/4885PTGER3 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.